Prelude Therapeutics Incorporated Overview
Pro stress-test →Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative targeted therapies for cancer patients. The company's portfolio includes PRT12396, a mutant-selective JAK2V617F inhibitor in Phase 1 development for polycythemia vera and myelofibrosis, and PRT13722, a first-in-class, orally bioavailable, potent and selective KAT6A degrader for ER+/HER2- breast cancer.
Strategic Profile
Pro stress-test →The company is on track to file an IND for PRT13722 in mid-2026 and to start a Phase 1 clinical trial in H2 2026. In April 2026, Prelude raised $90.0 million in gross proceeds through an underwritten offering, positioning the company for clinical advancement of its lead programs. The company leverages expertise in targeted protein degradation to develop differentiated oncology therapies.
Competitive Landscape
Pro stress-test →Prelude operates in precision oncology with a focus on areas of high unmet need for cancer patients. The company competes with established pharma and biotechs developing protein degraders and targeted therapies. Key areas of competition include JAK2V617F inhibition for myeloproliferative neoplasms and KAT6A-targeted therapies for hormone receptor-positive breast cancer.
Industry Context
Prelude Therapeutics Incorporated operates in Biotechnology / Precision Oncology.
Key facts
Founded: 2014 · Headquarters: Wilmington, US · Employees: N/A · Revenue: $33.3M · Market cap: N/A